Alzheimer's disease (AD) is one of major healthcare challenges for neuroscientist or clinicians. Approximately, 40 million people are suffered from dementia worldwide. Out of several life style related risk factors, diabetes mellitus (DM) is most devastating risk factor for AD which increased the risk of dementia 50%-150% in people with DM. Anti-diabetic drugs including insulin, glucagon like peptide 1 (GLP-1), dipeptidyl peptidase IV inhibitors ameliorated the amyloid pathology and cognitive deficits in experimental studies. Albiglutide, a GLP-1 agonist drug is used clinically for treatment of type-2 diabetes. Moreover, clinically, it is very safe and well tolerated drug. To overcome poor brain permeability of albiglutide, it can be administered intranasally. Hence, using this intranasal delivery method, albiglutide can directly be entered the brain, bypassing the blood-brain barrier. Therefore, the proposed study is planned to investigate the prophylactic and therapeutic potential of albiglutide using transgenic mice of AD. In this study, we will use recently developed single amyloid precursor protein knock-in mouse (APPNL-G-F/NL-G-F) model for AD. Here, we will use two protocols namely prophylactic and therapeutic. The drug will be administered intranasally at the dose of 10 mg/kg. The dose was calculated from human dose. In prophylactic protocol, drug treatment in mice will be started at the age of 2 months and will be continued till the age of 6 months. In therapeutic protocol, drug treatment in mice will be started at the age of 6 months and will be continued till the age of 12 months. The cognitive function in mice will be evaluated using various behavioral paradigms. The amyloid pathology, amyloid clearance mechanism, insulin and cholinergic dysfunction, oxidative stress and neuro-inflammatory markers will also be studied to understand the mechanism of drug. The expected outcomes from the present study would be helpful for generating an effective therapy for AD.